Article

"We are thrilled to welcome Daisy and Sam to the team and know their counsel will be invaluable as we continue to grow and scale our team, the company, and our drug discovery platform in 2022 and beyond," said Neil Dhawan, Ph.D., CEO and co-founder of Totus Medicines. "The next few years will be pivotal for Totus Medicines as we progress our mission of creating treatments for the world's most intractable diseases."

Chhokar brings nearly 20 years of human resources experience to Totus, where she will be responsible for leading the company's people and culture strategy as Chief People Officer. Prior to Totus, Chhokar served as the vice president and head of human resources at Nurix Therapeutics, and director of human resources at InterMune, another highly successful biotechnology organization.

"Totus Medicines is on a path of rapid growth as we continue to scale our drug discovery platform. Assembling the right team, including the world's leading data scientists, biologists, chemists, and more, will be critical to our successful expansion," Chhokar said. "I am looking forward to working with Neil and the Totus team to make this vision of treating the untreatable a reality."

Singer is a deeply experienced finance executive who has led analysis and evaluation of multiple biotechnology companies with a specific focus on oncology and gene editing. Before joining Totus as Chief Financial Officer, Singer served in leadership at Granahan Investment Management; Mistral Capital Partners; Wellington Management; Loomis, Sayles & Company; and Lehman Brothers.